^
    Back
    Association details:
    Biomarker:EGFR exon 20 insertion
    Cancer:Non Small Cell Lung Cancer
    Drug:cisplatin (DNA synthesis inhibitor) +
    pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Efficacy of various types of chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 in-frame insertions.

    Published date:
    05/19/2021
    Excerpt:
    Thirty-five advanced NSCLC patients harboring EGFR exon 20 in-frame insertions treated with chemotherapy were used to analyze, of which 7 received gemcitabine plus cisplatin (GC), 22 received pemetrexed plus cisplatin (PC), and 6 received taxol plus cisplatin (TC). ORRs were 31.82% for the patients received PC, 14.29% for GC, and 16.67% for TC....These results suggest that pemetrexed plus cisplatin may be the preferred chemotherapy for patients harboring EGFR exon 20 in-frame insertions...
    DOI:
    10.1200/JCO.2021.39.15_suppl.e21155